Simon Sturge, CEO of Vernalis plc,
Rings The NASDAQ Stock Market Closing Bell

Thursday, May 18, 2006
at NASDAQ's MarketSite
in New York City.

Vernalis plc [VNLS]

Simon Sturge, CEO of Vernalis plc (Nasdaq: VNLS) presides over the closing bell

Vernalis is a speciality bio-pharmaceutical company focused on products marketed to specialist neurologists. The Company has two marketed products, Frova(R) and Apokyn(R), and a development pipeline focused on neurology and central nervous system disorders. The company has seven products in clinical development and collaborations with leading, global pharmaceutical companies including Novartis, Biogen Idec and Serono. Vernalis has established a U.S. commercial operation to promote Apokyn(R) and co-promote Frova(R) alongside its North American licensing partner, Endo Pharmaceuticals, propelling the Company towards its goal of becoming a sustainable, self-funding, R&D-driven, speciality bio-pharmaceutical company. For further information about Vernalis, please visit http://www.vernalis.com.

On May 8, 2006, Vernalis announced top-line data from the Company's second Frova(R) (frovatriptan succinate) Phase III efficacy study for Prevention of Menstrual Migraine. The full press release, Frova(R) Meets Primary Endpoint in Second Phase III Study for Prevention of Menstrual Migraine; Data to be Included as Part of Supplemental NDA to FDA, can be accessed at http://www.vernalis.com/ver/nc/latestreleases/releases2006/2006-05-08/.

Click for larger pictures of the NASDAQ MarketSite. Additional Photographs for 5/18/2006 Download Hi-Res Quality Photo of this NASDAQ Market Open - Pictured: Simon Sturge, CEO of Vernalis plc, rings the Closing Bell These photos are Copyright 2006, The Nasdaq Stock Market Inc. and available for re-publication by the news media only. Any commercial use is strictly prohibited without the prior written consent of The Nasdaq Stock Market Inc. © Copyright 2006, The NASDAQ Stock Market, Inc. Reprinted with the permission of The Nasdaq Stock Market, Inc.